231 related articles for article (PubMed ID: 17409193)
1. Apoptotic mechanisms in mutant LRRK2-mediated cell death.
Iaccarino C; Crosio C; Vitale C; Sanna G; Carrì MT; Barone P
Hum Mol Genet; 2007 Jun; 16(11):1319-26. PubMed ID: 17409193
[TBL] [Abstract][Full Text] [Related]
2. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
Lu YW; Tan EK
J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
[TBL] [Abstract][Full Text] [Related]
3. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death.
Angeles DC; Gan BH; Onstead L; Zhao Y; Lim KL; Dachsel J; Melrose H; Farrer M; Wszolek ZK; Dickson DW; Tan EK
Hum Mutat; 2011 Dec; 32(12):1390-7. PubMed ID: 21850687
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
Drolet RE; Sanders JM; Kern JT
J Neurogenet; 2011 Dec; 25(4):140-51. PubMed ID: 22077787
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
7. Leucine-rich repeat kinase 2: relevance to Parkinson's disease.
Guo L; Wang W; Chen SG
Int J Biochem Cell Biol; 2006; 38(9):1469-75. PubMed ID: 16600664
[TBL] [Abstract][Full Text] [Related]
8. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.
Vancraenenbroeck R; Lobbestael E; Weeks SD; Strelkov SV; Baekelandt V; Taymans JM; De Maeyer M
Biochim Biophys Acta; 2012 Mar; 1824(3):450-60. PubMed ID: 22251894
[TBL] [Abstract][Full Text] [Related]
10. Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis.
Ohta E; Kubo M; Obata F
Biochem Biophys Res Commun; 2010 Jan; 391(1):242-7. PubMed ID: 19912990
[TBL] [Abstract][Full Text] [Related]
11. Identification of the autophosphorylation sites of LRRK2.
Kamikawaji S; Ito G; Iwatsubo T
Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
[TBL] [Abstract][Full Text] [Related]
12. Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate.
Krumova P; Reyniers L; Meyer M; Lobbestael E; Stauffer D; Gerrits B; Muller L; Hoving S; Kaupmann K; Voshol J; Fabbro D; Bauer A; Rovelli G; Taymans JM; Bouwmeester T; Baekelandt V
FASEB J; 2015 Jul; 29(7):2980-92. PubMed ID: 25854701
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich repeat kinase 2 associates with lipid rafts.
Hatano T; Kubo S; Imai S; Maeda M; Ishikawa K; Mizuno Y; Hattori N
Hum Mol Genet; 2007 Mar; 16(6):678-90. PubMed ID: 17341485
[TBL] [Abstract][Full Text] [Related]
14. Mutations in LRRK2 as a cause of Parkinson's disease.
Giasson BI; Van Deerlin VM
Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
[TBL] [Abstract][Full Text] [Related]
15. I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule.
Ohta E; Katayama Y; Kawakami F; Yamamoto M; Tajima K; Maekawa T; Iida N; Hattori S; Obata F
Biochem Biophys Res Commun; 2009 Dec; 390(3):710-5. PubMed ID: 19833102
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death.
Yoon JH; Mo JS; Kim MY; Ann EJ; Ahn JS; Jo EH; Lee HJ; Lee YC; Seol W; Yarmoluk SM; Gasser T; Kahle PJ; Liu GH; Belmonte JCI; Park HS
Biochim Biophys Acta Mol Cell Res; 2017 Dec; 1864(12):2356-2368. PubMed ID: 28888991
[TBL] [Abstract][Full Text] [Related]
17. [Advance of the study on LRRK2 gene in Parkinson's disease].
Zhang Y; Chen S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
[TBL] [Abstract][Full Text] [Related]
18. [Apoptosis of peripheral blood lymphocytes in patients with LRRK2-assoctated Parkinson's disease].
Usenko TS; Emel'ianov AK; Iakimovskiĭ AF; Bogan'kova NA; Vavilova TV; Shvartsman AL; Pchelina SN
Tsitologiia; 2012; 54(1):44-8. PubMed ID: 22567899
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 Parkinson's disease: from animal models to cellular mechanisms.
Lin CH; Tsai PI; Wu RM; Chien CT
Rev Neurosci; 2011; 22(4):411-8. PubMed ID: 21679126
[TBL] [Abstract][Full Text] [Related]
20. Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment.
Klein CL; Rovelli G; Springer W; Schall C; Gasser T; Kahle PJ
J Neurochem; 2009 Nov; 111(3):703-15. PubMed ID: 19712061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
